Previous close | 4.4550 |
Open | 4.5000 |
Bid | 4.5500 x 200 |
Ask | 4.5900 x 100 |
Day's range | 4.4700 - 4.6800 |
52-week range | 1.1110 - 6.7200 |
Volume | |
Avg. volume | 1,574,303 |
Market cap | 518.486M |
Beta (5Y monthly) | 2.37 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.2000 |
Earnings date | 13 May 2024 - 17 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 8.60 |
VANCOUVER, Wash. and NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter before market open on Tuesday, May 14, 2024. Absci management will webcast a corresponding conference call beginning at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time to discuss its business developments, financial and operating resul
Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
VANCOUVER, Wash. and NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 23rd Annual Needham Virtual Healthcare Conference. Absci management is scheduled to present on Monday, April 8th at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: investors.ab